TNFSF13B and systemic lupus erythematosus: The clinical efficacy of rituximab in treating systemic lupus erythematosus (SLE) demonstrates considerable variability, probably attributable to the following factors: elevated levels of BAFF (B-cell activating factor), B-cell reconstitution and the disease-specific high degree of heterogeneity in lupus.